ModernMedicine Resource Center More Topics

Hot Topics in Prostate Cancer

Active surveillance initiative raises adoption of strategyAn academic center/community practice collaboration increases use of surveillance among prostate cancer patients “through use of provider education and a standardized report card,” a study author said.
Assay predicts outcomes in men taking mCRPC agentExpression of androgen receptor splice variant 7 (AR-V7) in whole blood predicts worse cancer-related outcomes in patients with metastatic castration-resistant prostate cancer who are treated with abiraterone acetate (ZYTIGA).
Prostate HIFU lands in the U.S. Now what?"With all this uncertainty, the good news is that men will no longer need to travel to Canada or elsewhere for prostate HIFU therapy," writes Leonard G. Gomella, MD.
Prostate biopsy-related infections raise transfusion riskParadoxically, the authors of a large study did not find a negative effect in functional outcomes analyzed.
Use of observation for PCa varies widely among urologistsA CMS quality measure needs to be bidirectional, “specifying a rate of observation for low-risk disease and a rate of treatment for high-risk disease,” researchers say.
Peri-op transfusion raises short-term morbidity riskA retrospective analysis looks at the short-term morbidity associated with transfusion among patients in the National Surgical Quality Improvement database.
Study finds prostate Ca clones trackable by fusion biopsySpecific clones may have the potential for grade conversion, research suggests.
AS success rate strong in appropriate PCa patientsLarge study examines surveillance results in men with very low-, low-, intermediate-, and high-risk disease.
Greater long-term side effect risk with intermittent ADTIn men with metastatic prostate cancer, those assigned to intermittent androgen deprivation therapy have more ischemic and thrombotic events than those assigned to continuous androgen deprivation, according to Columbia University researchers.
No link between PDE-5 use, prostate Ca recurrenceNo significant relationship was found between use of a phosphodiesterase type-5 inhibitor and prostate cancer recurrence after treatment in a nested case-control study.